Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Retrieved on:
Wednesday, November 24, 2021
Patient, News, Security (finance), Regulation of tobacco by the U.S. Food and Drug Administration, Safety, Breakthrough therapy, Company, AML, Cancer, Clinical trial, Acute myeloid leukemia, HNSCC, SEC, SAN, HRAS, U.S. Securities and Exchange Commission, Therapy, NPM1, Physician, KMT2A, Nasdaq, Tipifarnib, Risk, Research, GLOBE, FDA, Postcholecystectomy syndrome, Webcast, KURA, Food, Pharmaceutical industry
Patients currently enrolled in the Phase 1b study may continue to receive KO-539, although no additional patients may be enrolled until the partial clinical hold is resolved.
Key Points:
- Patients currently enrolled in the Phase 1b study may continue to receive KO-539, although no additional patients may be enrolled until the partial clinical hold is resolved.
- Kura is working closely with the FDA and the site investigators to resolve the partial clinical hold as quickly as possible.
- Until the partial clinical hold is resolved, and the Company has more clarity regarding the impact on timing, Kura is suspending guidance on the completion of enrollment in the KOMET-001 Phase 1b study and determination of the recommended Phase 2 dose of KO-539.
- Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.